Physician profile
Robert C Kim
NPI 1396737870
$519.65
in general payments reported to CMS, 2019-2025
11 companies · $79.42 in 2025
The $79.42 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $40.54 · 2023: $47.77 · 2024: $212 · 2025: $79.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.54 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $160.31 | 2024 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $91.99 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $61.55 | 2024-2025 | Voyxact, Jynarque |
| Amgen INC. | $43.08 | 2019 | |
| Aurinia Pharma U.S., INC. | $38.95 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $30.00 | 2025 | |
| Mallinckrodt Hospital Products INC. | $29.57 | 2023 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $25.52 | 2019 | |
| Vifor Pharma, INC. | $20.02 | 2019 | |
| Baxter Healthcare | $15.58 | 2019 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.